Prostate cancer

CRPC: treatment in daily clinical practice

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.


Educational Objective: Gain insight into the appropriate selection of life-prolonging treatments for non-metastatic CRPC (nmCRPC) and metastatic CRPC (mCRPC).
Specialty: Urology, Medical oncology, Clinical oncology
Target Audience: CME (basic, intermediate), Residents (senior)
Latest update: April 2023

The optimal treatment choice/sequence for an individual patient with castration-resistant prostate cancer (CRPC) is challenging. This topic is limited to patients with a castrate testosterone level. Bone-protective agents fall beyond the scope of this topic.

Regulatory approval status of drugs for CRPC discussed in this topic (indications limited to the CRPC setting, status 3 April 2023)